Topical calcineurin inhibitors in pediatric atopic dermatitis: A critical analysis of current issues

Pediatric Drugs

Volumn 9, Issue 5, 2007, Pages 289-299

  Orlow, Seth J ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atopic dermatitis, treatment; Calcineurin inhibitors, therapeutic use; Children; Pimecrolimus, therapeutic use; Tacrolimus, therapeutic use

Indexed keywords

ANTIINFLAMMATORY AGENT; BETAMETHASONE; CALCINEURIN INHIBITOR; CLOCORTOLONE PIVALATE; CORTICOSTEROID; CYCLOSPORIN A; DRUG VEHICLE; EMOLLIENT AGENT; FLUTICASONE PROPIONATE; MOMETASONE FUROATE; PIMECROLIMUS; PNEUMOCOCCUS VACCINE; TACROLIMUS;

ATOPIC DERMATITIS; CANCER RISK; CLINICAL TRIAL; DELAYED HYPERSENSITIVITY; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ERYTHEMA; GRAFT REJECTION; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LONG TERM CARE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; NETHERTON DISEASE; NONHUMAN; PRIORITY JOURNAL; PRURITUS; RESPIRATORY TRACT INFECTION; REVIEW; RISK ASSESSMENT; SKIN BURNING SENSATION; SKIN CANCER; SKIN IRRITATION; SKIN MANIFESTATION; STIGNING; STINGING; TOXICITY TESTING; TREATMENT RESPONSE; VACCINATION;

EID: 35048898681     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200709050-00002     Document Type: Review

References (98)

1. Breuer K, Werfel T, Kapp A. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. Am J Clin Dermatol 2005; 6: 65-77
2. Laughter D, Istvan JA, Tofte SJ, et al. The prevalence of atopic dermatitis in Oregon schoolchildren. J Am Acad Dermatol 2000; 43: 649-55
3. Beltrani VS. Clinical features of atopic dermatitis. Immunol Allergy Clin North Am 2002; 22: 25-42
4. Leung DYM, Boguniewicz M, Howell MD, et al. New insights into atopic dermatitis. J Clin Invest 2004; 113: 651-7
5. Ellis CN, Kahler KH, Grueger J, et al. Cost effectiveness of management of mild-to-moderate atopic dermatitis with 1% pimecrolimus cream in children and adolescents 2-17 years of age. Am J Clin Dermatol 2006; 7: 133-9
6. Alomar A, Berth-Jones J, Bos JD, et al. The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol 2004; 151 Suppl. 70: 3-27
7. US Food and Drug Administration. FDA Public Health Advisory: Elidel (pimecrolimus) cream and Protopic (tacrolimus) ointment [online]. Available from URL: http://www.fda.gov/cder/drug/advisory/elidel_protopic.htm [Accessed 2007 Jul 9]
8. Novartis Pharmaceuticals Corporation. Elidel [prescribing information]. East Hanover (NJ): Novartis Pharmaceuticals Corporation, 2006
9. Astellas Pharma US, Inc. Protopic [prescribing information]. Deerfield (IL): Astellas Pharma US, Inc., 2006
10. Bieber T, Cork M, Ellis C, et al. Consensus statement on the safety profile of topical calcineurin inhibitors. Dermatology 2005; 211: 77-8
11. Berger TG, Duvic M, Van Voorhees AS, et al. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol 2006; 54: 818-23
12. Fonacier L, Spergel J, Charlesworth EN, et al. Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. Allergy Clin Immunol 2005; 115: 1249-53
13. Cockerell CJ. President's message: Elidel and Protopic alert [online]. Available from URL: http://www.aad.org [Accessed 2006 Feb 16]
14. Cockerell CJ. President's message: academy disappointed with restrictive new labeling for eczema medication, working to enhance dialogue with FDA [online]. Available from URL: http://www.aad.org/professionals/ AdvocacyGovRelSkin/tci_information.htm [Accessed 2006 Feb 16]
15. Spergel JM, Leung DYM. Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence. Curr Allergy Asthma Rep 2006; 6: 270-4
16. Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. J Allergy Clin Immunol 1998; 102: 637-44
17. Chapman MS, Schachner LA, Breneman D, et al. Tacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitis. J Am Acad Dermatol 2005; 53: S177-85
18. Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44: S58-64
19. Paller A, Eichenfield LF, Leung DYM, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001; 44: S47-57
20. Reitamo S, Wollenberg A, Schöpf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol 2000; 136: 999-1006
21. Ruzicka T, Bieber T, Schöpf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 1997; 337: 816-21
22. Schachner LA, Lamerson C, Sheehan MP, et al. Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study. Pediatrics 2005; 116: e334-42
23. Housman TS, Norton AB, Feldman SR, et al. Tacrolimus ointment: utilization patterns in children under age 2 years. Dermatol Online J 2004; 10: 2
24. Patel RR, Vander Straten MR, Korman NJ. The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis. Arch Dermatol 2003; 139: 1184-6
25. Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46: 495-504
26. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; 110: e2
27. Eichenfield LF, Lucky AW, Langley RGB, et al. Use of pimecrolimus cream 1% (Elidel® ) in the treatment of atopic dermatitis in infants and children: the effects of ethnic origin and baseline disease severity on treatment outcome. Int J Dermatol 2005; 44: 70-5
28. Ho VC, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003; 142: 155-62
29. Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002; 110: 277-84
30. Papp KA, Breuer K, Meurer M, et al. Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J Am Acad Dermatol 2005; 52: 247-53
31. Papp KA, Werfel T, Fölster-Holst R, et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. J Am Acad Dermatol 2005; 52: 240-6
32. Paul C, Cork M, Rossi AB, et al. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics 2006; 117: e118-28
33. Hoetzenecker W, Ecker R, Kopp T, et al. Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis. J Allergy Clin Immunol 2005; 115: 1276-83
34. Hoetzenecker W, Meingassner JG, Ecker R, et al. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol 2004; 122: 673-84
35. Kalthoff FS, Chung J, Musser P, et al. Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids. Clin Exp Immunol 2003; 133: 350-9
36. Meingassner JG, Kowalsky E, Schwendinger H, et al. Pimecrolimus does not affect Langerhans cells in murine epidermis. Br J Dermatol 2003; 149: 853-7
37. Queille-Roussel C, Paul C, Duteil L, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001; 144: 507-13
38. Faye A, Vilmer E. Post-transplant lymphoproliferative disorder in children: incidence, prognosis, and treatment options. Pediatr Drugs 2005; 7: 55-65
39. Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 222-30
40. Ormerod AD. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Br J Dermatol 2005; 153: 701-5
41. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005; 56: 29-44
42. US Food and Drug Administration. FDA public health advisory: Elidel (pimecrolimus) cream and Protopic (tacrolimus) Ointment [online]. Available from URL: http://www.fda.gov/cder/drug/advisory/elidel_protopic.htm [Accessed 2007 Jul 9]
43. Astellas Pharma US, Inc. Prograf [prescribing information]. Deerfield (IL): Astellas Pharma US, Inc., 2006
44. Harper J, Smith C, Rubins A, et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol 2005; 124: 695-9
45. Staab D, Pariser D, Gottlieb AB, et al. Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel® ) in infants with atopic dermatitis: a multicenter, 3-week, open-label study. Pediatr Dermatol 2005; 22: 465-71
46. Allen BR, Lakhanpaul M, Morris A, et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child 2003; 88: 969-73
47. Lakhanpaul M, Davies T, Allen BR, et al. Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%. Exp Dermatol 2006; 15: 138-41
48. Thaçi D, Steinmeyer K, Ebelin M-E, et al. Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective: an open study. Dermatology 2003; 207: 37-42
49. Van Leent EJM, Ebelin M-E, Burtin P, et al. Low systemic exposure after repeated topical application of pimecrolimus (Elidel® ), SDZ ASM 981 in patients with atopic dermatitis. Dermatology 2002; 204: 63-8
50. Allen A, Siegfried E, Silverman R, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 2001; 137: 747-50
51. Oji V, Beljan G, Beier K, et al. Topical pimecrolimus: a novel therapeutic option for Netherton syndrome. Br J Dermatol 2005; 153: 1067-8
52. Mahoney D. Topical aids Netherton's syndrome. Skin Allergy News 2006 Aug; 37: 2
53. Yan AC, Shah KN, Kubrak C, et al. A pilot study of the efficacy and safety of pimecrolimus 1% cream in the treatment of Netherton syndrome: interim results [poster P2401]. American Academy of Dermatology 65th Annual Meeting; 2007 Feb 2-6; Washington, DC
54. Drug Regulatory Affairs: Elidel (pimecrolimus) cream 1%. NDA 21-302 briefing document. 2005 Jan 25 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005- 4089b2_03_04_Elidel%20Novartis%20Briefing%20Bookredacted.pdf [Accessed 2007 Jul 9]
55. ICH Expert Working Group. Testing for carcinogenicity of pharmaceuticals. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. July 16, 1997 [online]. Available from URL: http://www.ich.org/LOB/media/MEDIA490.pdf [Accessed 2007 Jul 24]
56. Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 2005; 211: 174-87
57. US Food and Drug Administration. Pharmacokinetics/toxicokinetics [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/o5/briefing/ 2005-4089b2_01_07_Tox%20Review%20Redacted.pdf [Accessed 2005 Apr 5]
58. US Food and Drug Administration, Pediatric Advisory Committee. Discussion topic: risk evaluation, labeling, risk communication, and dissemination of information on potential cancer risk among pediatric patients treated for atopic dermatitis with topical dermatological immunosuppressants. Fujisawa Healthcare, Inc. February 15, 2005. Background package [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005- 4089b2_02_02_Protopic%20Fujisawa%20briefing.pdf [Accessed 2007 Jul 9]
59. Wijnen RMH, Ericzon B-G, Tiebosch ATMG, et al. Toxicology of FK506 in the cynomolgus monkey: a clinical, biochemical, and histopathological study. Transpl Int 1992; 5 Suppl. 1: S454-8
60. Jaracz E, Maher R, Simon D, et al. Safety profile of tacrolimus ointment: data from five years of post-marketing experience [poster P14]. American Academy of Dermatology 64th Annual Meeting; 2006 Mar 3-7; San Francisco (CA)
61. Socié G, Rosenfeld S, Frickhofen N, et al. Late clonal diseases of treated aplastic anemia. Semin Hematol 2000; 37: 91-101
62. Socié G, Henry-Amar M, Bacigalupo A, et al. Malignant tumors occurring after treatment of aplastic anemia. N Engl J Med 1993; 329: 1152-7
63. Arrelano F, Wentworth CM, Arana A, et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis [abstract]. J Invest Dermatol 2006; 126: 1682
64. Lindelöf B, Sigurgeirsson B, Gäbel H, et al. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 2000; 143: 513-9
65. Stockfleth E, Nindl I, Sterry W, et al. Human papillomaviruses in transplant-associated skin cancers. Dermatol Surg 2004; 30: 604-9
66. Yarosh DB, Pena AV, Nay SL, et al. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol 2005; 125: 1020-5
67. Doelker L, Tran C, Gkomouzas A, et al. Production and clearance of cyclobutane dipyrimidine dimers in UV-irradiated skin pretreated with 1% pimecrolimus or 0.1% triamcinolone acetonide creams in normal and atopic patients. Exp Dermatol 2006; 15: 342-6
68. Tran C, Lübbe J, Sorg O, et al. Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis. Dermatology 2005; 211: 341-7
69. Margolis D, Ole H, Bilker W. Is there an association between the use of topical calcineurin inhibitors and skin cancer [abstract]. J Invest Dermatol 2006; 126: 1-198
70. Ring J, Barker J, Behrendt H, et al. Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum. J Eur Acad Dermatol Venereol 2005; 19: 663-71
71. Stiehm ER, Roberts RL, Kaplan MS, et al. Pneumococcal seroconversion after vaccination for children with atopic dermatitis treated with tacrolimus ointment. J Am Acad Dermatol 2005; 53: S206-13
72. Edmunds WJ, Pebody RG, Aggerback H, et al. The sero-epidemiology of diphtheria in Western Europe. Epidemiol Infect 2000; 125: 113-25
73. de Melker H, Pebody RG, Edmunds WJ, et al. The seroepidemiology of measles in Western Europe. Epidemiol Infect 2001; 126: 249-59
74. Gold E, Fevrier A, Hatch MH, et al. Immune status of children one to four years of age as determined by history and antibody measurement. N Engl J Med 1973; 289: 231-5
75. Pebody RG, Edmunds WJ, Conyn-van Spaendonck M, et al. The seroepidemiology of rubella in western Europe. Epidemiol Infect 2000; 125: 347-57
76. Jyonouchi H. Delayed-type hypersensitivity [online]. Available from URL: http://www.emedicine.com/ped/topic558.htm [Accessed 2007 Jul 9]
77. Meingassner JG, Fahrngruber H, Bavandi A. Pimecrolimus inhibits the elicitation phase but does not suppress the sensitization phase in murine contact hypersensitivity, in contrast to tacrolimus and cyclosporine A. J Invest Dermatol 2003; 121: 77-80
78. Grassberger M, Steinhoff M, Schneider D, et al. Pimecrolimus: an anti-inflammatory drug targeting the skin. Exp Dermatol 2004; 13: 721-30
79. Niwa Y, Terashima T, Sumi H. Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. Br J Dermatol 2003; 149: 960-7
80. Roman D, Ulrich P, Paul G, et al. Determination of the effect of calcineurin inhibitors on the rat's immune system after KLH immunisation. Toxicol Lett 2004; 149: 133-40
81. Becker JC, Houben R, Vetter CS, et al. The carcinogenic potential of tacrolimus ointment beyond immune suppression: a hypothesis creating case report. BMC Cancer 2006; 6: 7
82. Niwa Y, Nasr I. Are we starting to induce skin cancer in order to avoid topical steroids? J Eur Acad Dermatol Venereol 2005 May; 19 (3): 387-9
83. Fleischer Jr AB, Ling M, Eichenfield L, et al. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections. J Am Acad Dermatol 2002; 47: 562-70
84. Torok HM, Maas-Irslinger R, Slayton RM. Clocortolone pivalate cream 0.1% used concomitantly with tacrolimus ointment 0.1% in atopic dermatitis. Cutis 2003; 72: 161-6
85. Nakahara T, Koga T, Fukagawa S, et al. Intermittent topical corticosteroid/tacrolimus sequential therapy improves lichenification and chronic papules more efficiently than intermittent topical corticosteroid/ emollient sequential therapy in patients with atopic dermatitis. J Dermatol 2004; 31: 524-8
86. Lee MJ, Pyszczynski N, Jusko WJ. Combined inhibition effects of tacrolimus and methylprednisolone on in vitro human lymphocyte proliferation. Immunopharmacol Immunotoxicol 1995; 17: 335-45
87. Siegfried E, Korman N, Molina C, et al. Safety and efficacy of early intervention with pimecrolimus cream 1% combined with corticosteroids for major flares in infants and children with atopic dermatitis. J Dermatolog Treat 2006; 17: 143-50
88. Eichenfield LF. Consensus guidelines in diagnosis and treatment of atopic dermatitis. Allergy 2004; 59 Suppl. 78: 86-92
89. Ellis C, Luger T. International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. Br J Dermatol 2003; 148 Suppl. 63: 3-10
90. Eichenfield LF, Hanifin JM, Luger TA, et al. Consensus conference on pediatric atopic dermatitis. J Am Acad Dermatol 2003; 49: 1088-95
91. Leung DYM, Nicklas RA, Li JT, et al. Disease management of atopic dermatitis: an updated practice parameter. Ann Allergy Asthma Immunol 2004; 93: S1-21
92. Sator P-G, Schmidt JB, Hönigsmann H. Comparison of epidermal hydration and skin surface lipids in healthy individuals and in patients with atopic dermatitis. J Am Acad Dermatol 2003; 48: 352-8
93. Boguniewicz M, Eichenfield LF, Hultsch T. Current management of atopic dermatitis and interruption of the atopic march. J Allergy Clin Immunol 2003; 112: S140-50
94. GlaxoSmithKline. Cutivate cream 0.05% [prescribing information]. Pittsburgh (PA): GlaxoSmithKline, 2002
95. Matsuda K, Katsunuma T, Iikura Y, et al. Adrenocortical function in patients with severe atopic dermatitis. Ann Allergy Asthma Immunol 2000; 85: 35-9
96. Friedlander SF, Hebert AA, Allen DB, et al. Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol 2002; 46: 387-93
97. Tan M-H, Lebwohl M, Esser AC, et al. The penetration of 0.005% fluticasone propionate ointment in eyelid skin. J Am Acad Dermatol 2001; 45: 392-6
98. Paller AS, McAlister RO, Doyle JJ, et al. Perceptions of physicians and pediatric patients about atopic dermatitis, its impact, and its treatment. Clin Pediatr (Phila) 2002; 41: 323-32